ELRA, a BCMA/CD3 bispecific antibody, was evaluated in the MM-9 phase 1/2 trial for patients with relapsed/refractory multiple myeloma (RRMM). The study explored different dosing regimens and observed comparable efficacy to previous studies, with manageable safety profiles but varying rates of cytokine release syndrome (CRS).

Key Points:

• ELRA (BCMA/CD3 bispecific antibody) studied in MM-9 trial for RRMM.
• Priming doses of 4 mg and 20 mg followed by 76 mg weekly or alternative schedules.
• Overall response rate (ORR) of 58.8%; median duration of response (DOR) and progression-free survival (PFS) varied by dosing regimen.
• Common adverse events included hematologic toxicities, infections, and CRS.
• Optimal priming regimen remains under evaluation; reducing dose frequency may impact efficacy.

Authors:
Matthew Pianko, Charlotte Pawlyn, Shang-Yi Huang, Tadao Ishida, Douglas W Sborov, Shinsuke Iida, Aravind Ramakrishnan, Reuben Benjamin, Rakesh Popat, Steven Schuster, Junya Kuroda, Chia-Jen Liu, Anne Philippe, Umberto Conte, Fangxin Hong, Erik Vandendries, Rafael Fonseca